|Oculus Enrolls First Patient in Study of Microcyn Hydrogel; DARA Announces Soltamox Distribution Partnership in Puerto Rico|
|By Staff and Wire Reports|
|Thursday, 16 August 2012 18:07|
Oculus Innovative Sciences, Inc. (Nasdaq: OCLS), announced it has enrolled the first patients in its double-blind, randomized clinical study evaluating an advanced Microcyn® hydrogel for management of hypertrophic or keloid scars under an FDA-reviewed protocol.
The company plans to complete its 40-patient trial and provide top-line data by mid-2013 calendar year. The study design calls for recruitment of up to 40 patients at four different U.S. sites, which are Albuquerque, NM, High Point, NC, Austin, TX and College Station, TX.
DARA BioSciences, Inc. (Nasdaq: DARA) announced it has entered into an exclusive distribution agreement with Seyer Pharmatec Inc. for the sale and distribution of Soltamox (tamoxifen citrate, oral solution) in the Commonwealth of Puerto Rico. DARA plans to launch Soltamox later this year.
After a competitive multi-state process, Accelr8 Technology Corporation (NYSE MKT: AXK) today announces that it is moving its headquarters from Denver, CO to Tucson, AZ.
Alliqua, Inc. (OTCBB: ALQA) ("Alliqua" or the "Company"), an advanced biopharmaceutical company focused on the development, manufacturing and distribution of proprietary transdermal wound care and drug delivery technologies, today announced the addition of Dr. Harold Schoenhaus to Alliqua's Scientific Advisory Board ("SAB").
Axia Group (PINKSHEETS:AGIJ) management is of the opinion that this is a major event that warrants a public announcement to its followers and shareholders.
EncounterCare Solutions, Inc. (PINKSHEETS: ECSL) today announced that it has retained CCG Investor Relations to provide investor and corporate communications services for the company. CCG will develop and implement a comprehensive investor relations program for EncounterCare Solutions as well as execute market awareness initiatives to increase exposure throughout the investment community.
Home Health International Inc. (PINKSHEETS: HHII), a Medicare-certified home health agency and durable medical equipment (DME) supplier, announced today that the Company is in talks with a physician group for exclusive referrals for home health services.
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, today reported preliminary results from Phase 1 studies of LX2931 and LX7101.
The Infectious Disease Research Institute (IDRI), a Seattle-based non-profit research organization that is a leading developer of adjuvants used in vaccines combating infectious disease, and Medicago Inc. (TSX: MDG) (OTCQX: MDCGF), a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), announce that they have been cleared by the U.S. Food and Drug Administration (FDA) to initiate a Phase 1 clinical trial for an H5N1 Avian Influenza VLP vaccine candidate ("H5N1 vaccine").
Oncolytics Biotech Inc. (TSX:ONC, NASDAQ: ONCY) today announced that it has completed patient enrollment in its U.S. Phase I clinical trial using REOLYSIN in combination with FOLFIRI (Folinic Acid (leucovorin) with Fluorouracil (5-FU) and Irinotecan) in patients with oxaliplatin refractory, Kras mutant colorectal cancer (REO 022).
Oncolytics Biotech Inc. (TSX:ONC) (NASDAQ: ONCY) today announced that it has completed patient enrollment in its U.K. Phase I clinical trial using intravenously-administered REOLYSIN in combination with cyclophosphamide in patients with advanced malignancies (REO 012).
Perrigo Company (Nasdaq: PRGO; TASE) today announced results for its fourth quarter and full year ended June 30, 2012.
Solos Endoscopy, Inc. (OTCPK: SNDY) is pleased to announce that the Company has posted its financial results for the Period Ended June 30, 2012. Solos Endoscopy posted Total Assets of $2,426,883 compared to Total Liabilities of just $214,827 for the same period.
WuXi PharmaTech (NYSE: WX) today announced that its toxicology facility in Suzhou had received a Certificate of Good Laboratory Practice (GLP) from the State Food and Drug Administration (SFDA) of the People's Republic of China after successfully passing two GLP inspections conducted by the SFDA.